the elucidation of the mechanisms of hydroxychloroquine for skin lesions in connective tissue diseases

1. 羟氯喹（HCQ）在日本不是一种被批准的药物。我们进行了一项初步研究，对日本难治性CLE患者给予HCQ后皮肤病变改善程度进行评估。此外，还对4家医院27例给予HCQ治疗的患者进行了合作评价。我们在医学期刊上发表了研究结果。2. 几乎没有关于用HCQ处理动物的实验的文章。我们将HCQ给予MRL/lpr小鼠，SLE模型小鼠伴le样皮损，并检测其对le样皮损的影响。我们在IID 2013上报道了结果。3. 我们计划给blm诱导的硬化皮肤小鼠注射HCQ。在本研究开始之前，为了研究该模型小鼠皮肤硬化的机制，我们使用该模型小鼠检测了UVA1照射对硬化皮肤的影响。我们在ICCLE 2013上报告了结果。

1. Hydroxychloroquine (HCQ) is not an approved drug in Japan. We conducted the pilot study that Japanese refractory CLE cases who were administrated HCQ were evaluated about the degree of the improvement of the skin lesions. More, 27 patients who were administrated HCQ at 4 hospitals were also evaluated in cooperation. We reported the results in medical journals. 2. There are almost no articles about the experiments on animals which were treated with HCQ. We administrated HCQ to MRL/lpr mice, model mice for SLE with LE-like skin lesions, and examined its effects on LE-like lesions. We reported the results in IID 2013. 3. We planned the study that BLM-induced sclerotic skin mice were administrated HCQ. Before the start of this study, for the investigation of the mechanisms of the skin sclerosis in this model mice skin, we examined the effects of UVA1 irradiation for sclerotic skin using this model mice. We reports the results in ICCLE 2013.